HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on TG Therapeutics (NASDAQ:TGTX) and maintained a price target of $49.
August 06, 2024 | 6:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on TG Therapeutics and maintained a price target of $49.
The reiteration of a Buy rating and a maintained price target of $49 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100